Anna V Hoekstra1, J Julie Kim, Pacita Keh, Julian C Schink. 1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, USA. annahoekstra@sbcglobal.net
Abstract
BACKGROUND: Fertility-sparing treatment may be offered as an alternative to standard surgical management of early-stage, well-differentiated endometrial cancer in young women. Immunostaining for progesterone receptor (PR) status is not currently part of the standard workup before treatment recommendations are made. CASE: We describe a 29-year-old woman who used oral contraceptive pills on a long-term basis in whom early-stage, well-differentiated endometrial cancer was diagnosed. Progestin therapy failed and the tumor was subsequently found to be PR negative. CONCLUSION: Combination oral contraceptive pills may stimulate clonal expansion of endometrial cells that lack PR, leading to endometrial adenocarcinoma unresponsive to progestin therapy. Consideration should be given to PR immunostaining for confirmation of the receptor status and evaluation of appropriate management options when counseling patients about fertility-sparing therapy.
BACKGROUND: Fertility-sparing treatment may be offered as an alternative to standard surgical management of early-stage, well-differentiated endometrial cancer in young women. Immunostaining for progesterone receptor (PR) status is not currently part of the standard workup before treatment recommendations are made. CASE: We describe a 29-year-old woman who used oral contraceptive pills on a long-term basis in whom early-stage, well-differentiated endometrial cancer was diagnosed. Progestin therapy failed and the tumor was subsequently found to be PR negative. CONCLUSION: Combination oral contraceptive pills may stimulate clonal expansion of endometrial cells that lack PR, leading to endometrial adenocarcinoma unresponsive to progestin therapy. Consideration should be given to PR immunostaining for confirmation of the receptor status and evaluation of appropriate management options when counseling patients about fertility-sparing therapy.
Authors: Laura Renkonen-Sinisalo; Ralf Bützow; Arto Leminen; Pentti Lehtovirta; Jukka-Pekka Mecklin; Heikki J Järvinen Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Pedro T Ramirez; Michael Frumovitz; Diane C Bodurka; Charlotte C Sun; Charles Levenback Journal: Gynecol Oncol Date: 2004-10 Impact factor: 5.482
Authors: Cornelia L Trimble; Michael Method; Mario Leitao; Karen Lu; Olga Ioffe; Moss Hampton; Robert Higgins; Richard Zaino; George L Mutter Journal: Obstet Gynecol Date: 2012-11 Impact factor: 7.661
Authors: Tae Hoon Kim; Dong-Kee Lee; Sung-Nam Cho; Grant D Orvis; Richard R Behringer; John P Lydon; Bon Jeong Ku; Adrienne S McCampbell; Russell R Broaddus; Jae-Wook Jeong Journal: Cancer Res Date: 2013-06-27 Impact factor: 12.701
Authors: Tae Hoon Kim; Jung-Yoon Yoo; Zhong Wang; John P Lydon; Shikha Khatri; Shannon M Hawkins; Richard E Leach; Asgerally T Fazleabas; Steven L Young; Bruce A Lessey; Bon Jeong Ku; Jae-Wook Jeong Journal: PLoS Genet Date: 2015-09-17 Impact factor: 5.917